Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Seung Hwan Shin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study
Choi, S., Byun, J. M., Park, S. S., Han, J., Oh, S., Jung, S., Park, H., Han, S., Lee, J. Y., Koh, Y., Jeon, Y. W., Yahng, S. A., Shin, S. H., Yoon, S. S. & Min, C. K., Feb 2025, In: Transplantation and Cellular Therapy. 31, 2, p. 74.e1-74.e11Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study
Oh, S., Park, S. S., Lee, J. Y., Yoon, J. H., Lee, S. E., Kim, H. J., Shin, S. H., Jeon, Y. W., Yahng, S. A., Jung, J., Ahn, A., Kim, M. & Min, C. K., Dec 2025, In: Blood Research. 60, 1, 54.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study
the Catholic Research Network for Multiple Myeloma (CAREMM-2002 study), Dec 2024, In: Blood Research. 59, 1, 24.Research output: Contribution to journal › Letter › peer-review
Open Access3 Scopus citations -
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1
Park, S., Bang, S. Y., Kwag, D., Lee, J. H., Kim, T. Y., Lee, J., Min, G. J., Park, S. S., Yahng, S. A., Jeon, Y. W., Shin, S. H., Yoon, J. H., Lee, S. E., Cho, B. S., Eom, K. S., Kim, Y. J., Lee, S., Min, C. K., Cho, S. G. & Lee, J. W. & 1 others, , Jun 2024, In: Bone Marrow Transplantation. 59, 6, p. 813-823 11 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
Byun, J. M., Park, S. S., Yoon, S. S., Ahn, A., Kim, M., Lee, J. Y., Jeon, Y. W., Shin, S. H., Yahng, S. A., Koh, Y. & Min, C. K., Jun 2023, In: Blood Research. 58, 2, p. 83-90 8 p.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations